[{"orgOrder":0,"company":"Polaris Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Arginine","graph1":"Oncology","graph2":"Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Polaris Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polaris Group \/ Inapplicable"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Arginine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Polaris Group \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Polaris Group \/ Inapplicable"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"Arginine","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Polaris Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Polaris Group \/ Inapplicable"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TURKEY","productType":"Enzyme","year":"2025","type":"Agreement","leadProduct":"Pegargiminase","moa":"||Arginine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Polaris Group \/ Polaris Group","highestDevelopmentStatusID":"9","companyTruncated":"Polaris Group \/ Polaris Group"}]

Find Clinical Drug Pipeline Developments & Deals by Polaris Group

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Under the agreement, Polaris will holds the rights for commercialization of ADI-PEG 20 (pegargiminase). It is being evaluated in late-satge for the treatment of malignant pleural mesothelioma

                          Product Name : ADI-PEG 20

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          April 15, 2025

                          Lead Product(s) : Pegargiminase,Cisplatin,Pemetrexed

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Recipient : Erkim

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : ADI-PEG 20 (pegylated arginine deiminase, pegargiminase) is designed to deplete the external supply of arginine, and is being investigated for Non-Alcoholic Steatohepatitis (NASH).

                          Product Name : ADI-PEG 20

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          November 29, 2023

                          Lead Product(s) : Pegargiminase

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : ADI-PEG 20 (pegargiminase) ia arginie degrader, which is being evaluated in phase 2/3 clinical trials in combination with cisplatin & pemetrexed for the treatment of malignant pleural mesothelioma.

                          Product Name : ADI-PEG 20

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          November 16, 2023

                          Lead Product(s) : Pegargiminase,Cisplatin,Pemetrexed

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : ADI-PEG 20 (pegargiminase) is an Arginine Degrader Enzyme drug candidate, which is currently being evaluating clinical trial studies with patients for the treatment of Leiomyosarcoma.

                          Product Name : ADI-PEG 20

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          April 12, 2023

                          Lead Product(s) : Pegargiminase,Docetaxel,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank